Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Regeneron Pharmaceuticals, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. Pacific Time, with a webcast available on their website [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases, with a strong emphasis on homegrown treatments [2] - The company’s product pipeline addresses a wide range of conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [2] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and new classes of bispecific antibodies, enhancing drug development [3] - The company is advancing genetic medicine platforms and leveraging data from the Regeneron Genetics Center to identify innovative treatment targets [3]